AACR2024

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

AACR2024
Dec 23, 2024, 16:55 | Insight
Bernard Fox: Earle A. Chiles Research Institute's tripling of response rates for patients with head and neck cancer
Bernard Fox, Co-Founder, President and CEO of UbiVac, shared a post on LinkedIn by Earle…
Jul 24, 2024, 14:40 | Blog
Bernard Fox: 100 New Cancer Immunotherapy drug approvals in the next decade
Bernard Fox, Co-Founder and CEO of UbiVac, shared on LinkedIn: "100 New Cancer Immunotherapy drug approvals…
May 8, 2024, 13:20 | Drugs
CDK4 inhibitor on the horizon - Oncology Experts
Oncology Experts shared on LinkedIn: "PF-07220060, another CDK4 inhibitor on the horizon. Reported by Pfizer…
May 1, 2024, 11:59 | Opinion
Bernard A. Fox: Dark Matter is the biggest breakthrough in cancer immunotherapy of the last 3 years
Bernard A. Fox, Co-Founder and CEO of UbiVac shared on LinkedIn: “Best response rate for recurrent…
Apr 16, 2024, 13:31 | Blog
Sarabjot Pabla: What an incredible opportunity it was to be part of AACR2024
Sarabjot Pabla, Head of Clinical and Research Bioinformatics at OmniSeq, shared on their LinkedIn: ''What…
Apr 11, 2024, 06:46 | Opinion
Maria Natalia Gandur Quiroga: The Hallmarks of Precancer
Maria Natalia Gandur Quiroga shared a post on X: "The Hallmarks of Precancer. AACR Journals,…
Apr 10, 2024, 17:11 | Blog
Lynn Schuchter: I only know a fraction of what rock star Lillian Siu is doing but can name a few
Lynn Schuchter shared the following post on X: "I only know a fraction of what…
Apr 9, 2024, 15:56 | Blog
We’ve been energized and inspired by our time at AACR2024 - Agenus
Agenus shared a post on LinkedIn: “We’ve been energized and inspired by our time at AACR2024.…
All: 8 Posts: 1 - 100
Special Coverage